
Gyrus Capital's Essential Pharma refinances, inks two deals
Essential Pharma, a UK pharmaceutical company backed by Gyrus Capital, has completed a refinancing providing capital to continue its organic and inorganic growth strategy.
Details remain undisclosed. The refinancing was an extension of the existing facilities, providing further firepower for acquisitions and allowing Gyrus to take a dividend recap, according to a source close to the situation.
In parallel with the refinancing, Essential Pharma completed two M&A deals in December.
It divested its 14-product portfolio, Essential Pharma Liquids Limited, to Rosemont Pharmaceuticals Limited. In conjunction with this divestiture, Essential Pharma also acquired Yorkdale Pharma Limited from Rosemont Pharmaceutical, adding five products to the Essential Pharma portfolio.
The company also expanded its global portfolio with product acquisitions for ocular and postpartum therapies from Novartis. Representing the worldwide rights (excluding US and India), these products are sold in more than 50 countries worldwide.
Gyrus Capital signed the acquisition of Essential Pharma in late 2019. The company was being acquired from its founding shareholders by the incumbent management, supported by a significant equity commitment from Gyrus's Cortex Fund, the deal-by-deal multi-asset vehicle that raised EUR 240m in 2019. Leverage was provided by Hayfin Capital Management.
Essential Pharma, based in Egham, Surrey, licences and sells speciality pharmaceuticals in the UK and European markets. According to its website, it specialises in "low-volume, difficult-to-manufacture but clinically well-established pharmaceutical products".
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater